Back to Browse Journals » Therapeutics and Clinical Risk Management » Volume 7

Atrial fibrillation and the use of oral bisphosphonates

Authors Michael Pazianas, Cyrus Cooper, Yiting Wang, et al

Published Date March 2011 Volume 2011:7 Pages 131—144

DOI http://dx.doi.org/10.2147/TCRM.S17899

Published 22 March 2011

Michael Pazianas1, Cyrus Cooper1,2, Yiting Wang3, Jeff L Lange4, R Graham G Russell1,5
1The Botnar Research Centre, Oxford University, Oxford, UK; 2MRC Epidemiology Resource Centre, University of Southampton, Southampton, UK; 3Warner Chilcott Pharmaceuticals, USA; 4Procter & Gamble Company, Cincinnati, OH, USA; 5The Mellanby Centre for Bone Research, Sheffield University, Sheffield, UK

Background: Epidemiological studies investigating a possible association between bisphosphonates and atrial fibrillation (AF) have reported conflicting findings. The objective of our study was to determine whether exposure to oral nitrogen-containing bisphosphonates alendronate and risedronate are associated with increased incidence of atrial fibrillation.
Methods: In a retrospective cohort study we analyzed data from three large independent databases, two from the United States (MarketScan® and Ingenix®) and one from the United Kingdom (THIN). 144,548 women, age 50–89, bisphosphonate users during 2002–2005 were compared to 668,891 sex- and age-matched controls (1:4). Our primary outcome measure was new incident atrial fibrillation for up to three years; Cox models adjusted for disease and drug history were used to estimated relative risks.
Results: We identified a total of 8,001, 1,984, and 817 AF cases in oral bisphosphonate users and nonusers during 744,340 (MarketScan), 243,898 (Ingenix), and 148,779 (THIN) person-years of follow-up, respectively. Compared to nonusers, overall adjusted relative risk (adjRR) (95% confidence interval [CI]) for AF in oral bisphosphonates users was 0.92 (0.85–0.99; MarketScan), 1.00 (0.87–1.16; Ingenix), and 0.97 (0.79–1.20; THIN); overall adjRR (95% CI) for any cardiac dysrrhythmia for MarketScan was 1.01 (0.98–1.05), Ingenix 1.06 (0.99–1.13), and THIN 0.97 (0.79–1.20).
Conclusions: In all three databases from the two countries, the risk of AF or cardiac dysrrhythmia was not increased in postmenopausal women treated for up to three years with oral alendronate or risedronate.

Keywords: atrial fibrillation, chemically induced osteoporosis, drug therapy, alendronate or risedronate, bisphosphonates, adverse effects
 

Download Article [PDF] View Full Text [HTML] 

Creative Commons License This work is published by Dove Medical Press Limited, and licensed under Creative Commons Attribution - Non Commercial (unported, v3.0) License. The full terms of the License are available at http://creativecommons.org/licenses/by-nc/3.0/. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. Permissions beyond the scope of the License are administered by Dove Medical Press Limited. Information on how to request permission may be found at: http://www.dovepress.com/permissions.php

Other article by this author:

Eliminating the need for fasting with oral administration of bisphosphonates

Pazianas M, Abrahamsen B, Ferrari S, Russell RGG

Therapeutics and Clinical Risk Management 2013, 9:395-402

Published Date: 18 October 2013

Readers of this article also read:

Increasing the oral bioavailability of poorly water-soluble carbamazepine using immediate-release pellets supported on SBA-15 mesoporous silica

Wang Z, Chen B, Quan G, Li F, Wu Q, Dian L, Dong Y, Li G, Wu C

International Journal of Nanomedicine 2012, 7:5807-5818

Published Date: 22 November 2012

Inactivation of microbial infectiousness by silver nanoparticles-coated condom: a new approach to inhibit HIV- and HSV-transmitted infection

Mohammed Fayaz A, Ao Z, Girilal M, Chen L, Xiao X, Kalaichelvan PT, Yao X

International Journal of Nanomedicine 2012, 7:5007-5018

Published Date: 24 September 2012

Self-assembled supramolecular nano vesicles for safe and highly efficient gene delivery to solid tumors

Li W, Li H, Li J, Wang H, Zhao H, Zhang L, Xia Y, Ye Z, Gao J, Dai J, Wang H, Guo Y

International Journal of Nanomedicine 2012, 7:4661-4677

Published Date: 22 August 2012

A case of lethal soft tissue injuries due to assault

Yanagawa Y, Kanawaku Y, Kanetake J

Open Access Emergency Medicine 2012, 4:17-19

Published Date: 28 May 2012

Effects of protein and omega-3 supplementation, provided during regular dialysis sessions, on nutritional and inflammatory indices in hemodialysis patients

Mat Daud ZA, Tubie B, Adams J, Quainton T, Osia R, Tubie S, Kaur D, Khosla P, Sheyman M

Vascular Health and Risk Management 2012, 8:187-195

Published Date: 20 March 2012

Role of zoledronic acid in the prevention and treatment of osteoporosis

Räkel A, Boucher A, Ste-Marie L-G

Clinical Interventions in Aging 2011, 6:89-99

Published Date: 28 March 2011

Biocompatibility of Fe3O4/DNR magnetic nanoparticles in the treatment of hematologic malignancies

Weiwei Wu, Baoan Chen, Jian Cheng, et al

International Journal of Nanomedicine 2010, 5:1079-1084

Published Date: 2 December 2010

Current options for the treatment of Paget’s disease of the bone

Daniela Merlotti, Luigi Gennari, Giuseppe Martini, et al

Open Access Rheumatology: Research and Reviews 2009, 1:107-120

Published Date: 23 July 2009

Biphosphonates-related osteonecrosis of the jaw: Clinical and physiopathological considerations

Alberto Borgioli, Christian Viviani, Marco Duvina, Leila Brancato, Giuseppe Spinelli, et al

Therapeutics and Clinical Risk Management 2009, 5:217-227

Published Date: 27 February 2009